Nutrition and nutraceutical supplements in the treatment of hypertension

References

• Houston MC. Treatment of hypertension with nutraceuticals. Vitamins, antioxidants and minerals. Expert Rev. Cardiovasc. Ther.5(4), 681–691 (2007).
   PubMedGoogle Scholar
• Eaton SB, Eaton SB III, Konner MJ. Paleolithic nutrition revisited: a twelve-year retrospective on its nature and implications. Eur. J. Clin. Nutr.51, 207–216 (1997).
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC-7). JAMA289, 2560–2572 (2003).
   PubMed Web of Science ®Google Scholar
• Houston MC. New insights and approaches to reduce end organ damage in the treatment of hypertension: subsets of hypertension approach. Am. Heart J.123, 1337–1367 (1992).
   PubMed Web of Science ®Google Scholar
• Wolf-Maier K, Cooper RS, Banegas JR et al. Hypertension prevalence and blood pressure levels in six European countries, Canada and the United States. JAMA289, 2363–2369 (2003).
   PubMed Web of Science ®Google Scholar
• Nayak DU, Karmen C, Frishman WH, Vakili BA. Antioxidant vitamins and enzymatic and synthetic oxygen-derived free radical scavengers in the prevention and treatment of cardiovascular disease. Heart Dis.3, 28–45 (2001).
   PubMedGoogle Scholar
• Kitiyakara C, Wilcox C. Antioxidants for hypertension. Curr. Opin. Nephrol. Hypertens.7, 531–538 (1998).
   PubMed Web of Science ®Google Scholar
• Russo C, Olivieri O, Girelli D et al. Antioxidant status and lipid peroxidation in patients with essential hypertension. J. Hypertens.16, 1267–1271 (1998).
   PubMed Web of Science ®Google Scholar
• Tse WY, Maxwell SR, Thomason H et al. Antioxidant status in controlled and uncontrolled hypertension and its relationship to endothelial damage. J. Hum. Hypertens.8, 843–849 (1994).
   PubMed Web of Science ®Google Scholar
• Galley HF, Thornton J, Howdle PD, Walker BE, Webster NR. Combination oral antioxidant supplementation reduces blood pressure. Clin. Sci.92, 361–365 (1997).
   PubMed Web of Science ®Google Scholar
• Dhalla NS, Temsah RM, Netticadam T. The role of oxidative stress in cardiovascular diseases. J. Hypertens.18, 655–673 (2000).
   PubMed Web of Science ®Google Scholar
• Saez G, Tormos MC, Giner V, Lorano JV, Chaves FJ. Oxidative stress and enzymatic antioxidant mechanisms in essential hypertension. Am. J. Hypertens.14, 248A (2001) (Abstract P-653).
   PubMed Web of Science ®Google Scholar
• Eaton SB, Eaton SB III, Konner MJ. Paleolithic nutrition revisited: a twelve-year retrospective on its nature and implications. Eur. J. Clin. Nutr.51, 207–216 (1997).
   PubMed Web of Science ®Google Scholar
• Berdanier CD. Nutrient–gene interactions. In: Present Knowledge in Nutrition (7th Edition). Ziegler EE, Filer LJ Jr (Eds). ILSI Press, Washington DC, USA, 574–580 (1996).
   Google Scholar
• Talmud PJ, Waterworth DM. In vivo and in vitro nutrient–gene interactions. Curr. Opin. Lipidol.11, 31–36 (2000).
   PubMed Web of Science ®Google Scholar
• Broadhurst CL. Balanced intakes of natural triglycerides for optimum nutrition: an evolutionary and phytochemical perspective. Med. Hypoth.49, 247–261 (1997).
   PubMed Web of Science ®Google Scholar
• Kotchen TA, McCarron DA. AHA Science Advisory. Dietary electrolytes and blood pressure. Circulation98, 613–617 (1998).
   PubMedGoogle Scholar
• Cutler JA, Follmann, Allender PS. Randomized trials of sodium reduction: an overview. Am. J. Clin. Nutr.65, 643S–651S (1997).
   PubMed Web of Science ®Google Scholar
• Svetkey LP, Sacks FM, Obarzanek E et al. The DASH diet, sodium intake and blood pressure (the DASH-Sodium Study): rationale and design. J. Am. Diet. Assoc.99, S96–S104 (1999).
   PubMed Web of Science ®Google Scholar
• Messerli FH, Schmieder RE, Weir MR. Salt: a perpetrator of hypertensive target organ disease? Arch. Intern. Med.157, 2449–2452 (1997).
   PubMed Web of Science ®Google Scholar
• Kawasaki T, Delea CS, Bartter FC, Smith H. The effect of high-sodium and low-sodium intakes on blood pressure and other related variables in human subjects with idiopathic hypertension. Am. J. Med.64, 193–198 (1978).
   PubMed Web of Science ®Google Scholar
• Weinberger MH. Salt sensitivity of blood pressure in humans. Hypertension27, 481–490 (1996).
   PubMed Web of Science ®Google Scholar
• Morimoto A, Usu T, Fujii T et al. Sodium sensitivity and cardiovascular events in patients with essential hypertension. Lancet350, 1734–1737 (1997).
   PubMed Web of Science ®Google Scholar
• Houston MC, Harper KJ. Potassium, magnesium, and calcium: their role in both the cause and treatment of hypertension. J. Clin. Hypertens.10(7 Suppl. 2), 3–11 (2008).
   PubMed Web of Science ®Google Scholar
• Whelton PK, He J. Potassium in preventing and treating high blood pressure. Semin. Nephrol.19, 494–499 (1999).
   PubMed Web of Science ®Google Scholar
• Gu D, He J, Xigui W, Duan X, Whelton PK. Effect of potassium supplementation on blood pressure in Chinese: a randomized, placebo-controlled trial. J. Hypertens.19, 1325–1331 (2001).
   PubMed Web of Science ®Google Scholar
• Widman L, Wester PO, Stegmayr BG, Wirell MP. The dose dependent reduction in blood pressure through administration of magnesium: a double blind placebo controlled cross-over trial. Am. J. Hypertens.6, 41–45 (1993).
   PubMed Web of Science ®Google Scholar
• Laurant P, Touyz RM. Physiological and pathophysiological role of magnesium in the cardiovascular system: implications in hypertension. J. Hypertens.18, 1177–1191 (2000).
   PubMed Web of Science ®Google Scholar
• McCarron DA. Role of adequate dietary calcium intake in the prevention and management of salt sensitive hypertensive. Am. J. Clin. Nutr.65, 712S–716S (1997).
   PubMed Web of Science ®Google Scholar
• Resnick LM. Calcium metabolism in hypertension and allied metabolic disorders. Diabetes Care14, 505–520 (1991).
   PubMed Web of Science ®Google Scholar
• Garcia Zozaya JL, Padilla Viloria M. Alterations of calcium, magnesium, and zinc in essential hypertension: their relation to the rennin–angiotensin–aldosterone system. Invest. Clin.38, 27–40 (1997).
   PubMedGoogle Scholar
• Bergomi M, Rovesti S, Vinceti M et al. Zinc and copper status and blood pressure. J. Trace Elem. Med. Biol.11, 166–169 (1997).
   PubMed Web of Science ®Google Scholar
• Stamler J, Elliott P, Kesteloot H et al. Inverse relation of dietary protein markers with blood pressure. Findings for 10,020 men and women in the Intersalt Study. Intersalt Cooperative Research Group. International study of salt and blood pressure. Circulation94, 1629–1634 (1996).
   PubMed Web of Science ®Google Scholar
• Elliott P, Dennis B, Dyer AR et al. Relation of dietary protein (total, vegetable, animal) to blood pressure: INTERMAP epidemiologic study. Presented at: 18th Scientific Meeting of the International Society of Hypertension. Chicago, IL, USA, 20–24 August 2000.
   Google Scholar
• FitzGerald RJ, Murray BA, Walsh DJ. Hypotensive peptides from milk proteins. J. Nutr.134(4), 980S–988S (2004).
   PubMed Web of Science ®Google Scholar
• Pins JJ, Keenan JM. Effects of whey peptides on cardiovascular disease risk factors. J. Clin. Hypertens.8(11), 775–782 (2006).
   Google Scholar
• Aihara K, Kajimoto O, Takahashi R, Nakamura Y. Effect of powdered fermented milk with Lactobacillus helveticus on subjects with high-normal blood pressure or mild hypertension. J. Am. Coll. Nutr.24(4), 257–265 (2005).
   PubMed Web of Science ®Google Scholar
• Pins J, Keenan J. The antihypertensive effects of a hydrolyzed whey protein supplement. Cardiovasc. Drugs Ther.16(Suppl.), 68 (2002).
   Google Scholar
• Kawasaki T, Seki E, Osajima K et al. Antihypertensive effect of valyl–tyrosine, a short chain peptide derived from sardine muscle hydrolyzate, on mild hypertensive subjects. J. Hum. Hypertens.14, 519–523 (2000).
   PubMed Web of Science ®Google Scholar
• Kawasaki T, Jun CJ, Fukushima Y, Seki E. Antihypertensive effect and safety evaluation of vegetable drink with peptides derived from sardine protein hydrolysates on mild hypertensive, high-normal and normal blood pressure subjects. Fukuoka Igaku Zasshi93(10), 208–218 (2002).
   PubMedGoogle Scholar
• Begg DP, Sinclari AJ, Stahl LA, Garg ML, Jois M, Weisinger RS. Dietary proteins level interacts with omega-3 polyunsaturated fatty acid deficiency to induce hypertension. Am. J. Hypertens.23(2), 125–128 (2009).
   PubMed Web of Science ®Google Scholar
• Morris MC. Dietary fats and blood pressure. J. Cardiovasc. Risk1, 21–30 (1994).
   PubMedGoogle Scholar
• Mori TA, Bao DQ, Burke V, Puddey IB, Beilin LJ. Docosahexaenoic acid but not eicosapentaenoic acid lowers ambulatory blood pressure and heart rate in humans. Hypertension34, 253–260 (1999).
   PubMed Web of Science ®Google Scholar
• Bønaa KH, Bjerve KS, Straume B, Gram IT, Thelle D. Effect of eicosapentaenoic and docosahexanoic acids on blood pressure in hypertension: a population-based intervention trial from the Tromso study. N. Engl. J. Med.322, 795–801 (1990).
   PubMed Web of Science ®Google Scholar
• Mori TA, Burke V, Puddey I, Irish A. The effects of omega 3 fatty acids and coenzyme Q 10 on blood pressure and heart rate in chronic kidney disease: a randomized controlled trial. J. Hypertens.27(9), 1863–1872 (2009).
   PubMed Web of Science ®Google Scholar
• Ueshima H, Stamler J, Elliot B, Brown, CQ. Food omega 3 fatty acid intake of individuals (total, linolenic acid, long chain) and their blood pressure: INTERMAP study. Hypertension50(2), 313–319 (2007).
   PubMed Web of Science ®Google Scholar
• Mon TA. Omega 3 fatty acids and hypertension in humans. Clin. Exp. Pharmacol. Physiol.33(9), 842–846 (2006).
   PubMed Web of Science ®Google Scholar
• Eaton SB, Eaton SB III, Konner MJ. Paleolithic nutrition revisited: a twelve-year retrospective on its nature and implications. A review. Eur. J. Clin. Nutr.51, 207–216 (1997).
   PubMed Web of Science ®Google Scholar
• Chin JP. Marine oils and cardiovascular reactivity. Prostaglandins Leukot. Essent. Fatty Acids50, 211–222 (1994).
   PubMed Web of Science ®Google Scholar
• Ferrara LA, RaimondiS, d’Episcopa I. Olive oil and reduced need for antihypertensive medications. Arch. Intern. Med.160, 837–842 (2000).
   PubMedGoogle Scholar
• Thomsen C, Rasmussen OW, Hansen KW, Vesterlund M, Hermansen K. Comparison of the effects on the diurnal blood pressure, glucose, and lipid levels of a diet rich in monounsaturated fatty acids with a diet rich in polyunsaturated fatty acids in Type 2 diabetic subjects. Diabet. Med.12, 600–606 (1995).
   PubMed Web of Science ®Google Scholar
• He J, Whelton PK. Effect of dietary fiber and protein intake on blood pressure: a review of epidemiologic evidence. Clin. Exp. Hypertens.21, 785–796 (1999).
   PubMed Web of Science ®Google Scholar
• Simons S, Wollersheim H, Thien T. A systematic review on the influence of trial quality on the effets of garlic on blood pressure. Neth. J. Med.67(6), 212–219 (2009).
   PubMed Web of Science ®Google Scholar
• Reinhard KM, Coleman CI, Teevan C, Vacchani P. Effects of garlic on blood pressure in patients with and without systolic hypertension: a meta-analysis. Ann. Pharmacother.42(12), 1766–1771 (2008).
   PubMed Web of Science ®Google Scholar
• Hodgson JM, Puddey IB, Burke V, Beilin LJ, Jordan N. Effects on blood pressure of drinking green and black tea. J. Hypertens.17, 457–463 (1999).
   PubMed Web of Science ®Google Scholar
• Suetsuna K, Nakano T. Identification of an antihypertensive peptide from peptic digest of wakame (Undaria pinnatifida). J. Nutr. Biochem.11, 450–454 (2000).
   PubMed Web of Science ®Google Scholar
• Nakano T, Hidaka H, Uchida J, Nakajima K, Hata Y. Hypotensive effects of wakame. J. Jpn Soc. Clin. Nutr.20, 92 (1998).
   Google Scholar
• Krotkiewski M, Aurell M, Holm G, Grimby G, Szckepanik J. Effects of a sodium–potassium ion-exchanging seaweed preparation in mild hypertension. Am. J. Hypertens.4, 483–488 (1991).
   PubMed Web of Science ®Google Scholar
• Sherman DL, Keaney JF, Biegelsen ES et al. Pharmacological concentrations of ascorbic acid are required for the beneficial effect on endothelial vasomotor function in hypertension. Hypertension35, 936–941 (2000).
   PubMed Web of Science ®Google Scholar
• Ness AR, Khaw K-T, Bingham S, Day NE. Vitamin C status and blood pressure. J. Hypertens.14, 503–508 (1996).
   PubMed Web of Science ®Google Scholar
• Duffy SJ, Bokce N, Holbrook M et al. Treatment of hypertension with ascorbic acid. Lancet354, 2048–2049 (1999).
   PubMed Web of Science ®Google Scholar
• Enstrom JE, Kanim LE, Klein M. Vitamin C intake and mortality among a sample of the United States population. Epidemiology3, 194–202 (1992).
   PubMed Web of Science ®Google Scholar
• Block G, Jensen, CD, Norkus EP, Hudes M, Crawford PB. Vitamin C in plasma is inversely related to blood pressure and change in blood pressure during the previous year in young black and white women. Nutr. J.17(7), 35–46 (2008).
   Web of Science ®Google Scholar
• Hatzitolios A, Iliadis F, Katsiki N, Baltatzi M. Is the antihypertensive effet of dietary supplements via aldehydes reduction evidence based: a systemic review. Clin. Exp. Hypertens.30(7), 628–639 (2008).
   PubMed Web of Science ®Google Scholar
• Mahajan AS, Babbar R, Kansai N, Agarwai SK, Ray PC. Antihypertensive and antioxidant action of amlodipine and Vitamin C in patients of essential hypertension. J. Clin. Biochem. Nutr.402, 141–147 (2007).
   Google Scholar
• Ledlerc PC, Proulx, CD, Arquin G, Belanger S. Ascorbic acid decreases the binding affinity of the AT1 receptor for angiotensin II. Am. J. Hypertens.21(1), 67–71 (2009).
   Web of Science ®Google Scholar
• Plantinga Y, Ghiadone L, Magagna A, Biannarelli C. Supplementation with Vitamins C and E improves arterial stiffness and endothelial function in essential hypertensive patients. Am. J. Hypertens.20(4), 392–397 (2007).
   PubMed Web of Science ®Google Scholar
• Sato K, Dohi Y, Kojima M, Miyagawa K. Effects of ascorbic acid on ambulatory blood pressure in elderly patients with refractory hypertension. Arzneimittelforschung56(7), 535–540 (2006).
   PubMed Web of Science ®Google Scholar
• Block G, Mangels AR, Norkus EP, Patterson BH, Levander OA, Taylor PR. Ascorbic acid status and subsequent diastolic and systolic blood pressure. Hypertension37, 261–267 (2001).
   PubMed Web of Science ®Google Scholar
• National Center for Health Statistics; Fulwood R, Johnson CL, Bryner JD. Hematological and Nutritional Biochemistry Reference Data for Persons 6 Months–74 Years of Age: United States, 1976–1980. US Public Health Service, Washington DC, USA, Vital and Health Statistics series 11, No. 232, DHHS publication No. (PHS) 83–1682 (1982).
   Google Scholar
• Ward NC, Wu JH, Clarke MW, Buddy IB. Vitamin E effects on the treatment of hypertension in Type 2 diabetics. J. Hypertens.227, 227–234 (2007).
   Google Scholar
• Hanni LL, Huarfner LH, Sorensen OH, Ljunghall S. Vitamin D is related to blood pressure and other cardiovascular risk factors in middle-aged men. Am. J. Hypertens.8, 894–901 (1995).
   PubMed Web of Science ®Google Scholar
• Bednarski R, Donderski R, Manitius L. Role of vitamin D in arterial blood pressure control. Pol. Merkur. Lekarski136, 307–310 (2007).
   Google Scholar
• Li YC, Kong H, Wei M, Chen ZF. 1, 25 Dihydroxyvitamin D 3 is a negative endocrine regulator of the renin angiotensin system. J. Clin. Invest.110(2), 229–238 (2002).
   PubMed Web of Science ®Google Scholar
• Pfeifer M, Begerow B, Minne HW, Nachtigall D, Hansen C. Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J. Clin. Endocrinol. Metab.86, 1633–1637 (2001).
   PubMed Web of Science ®Google Scholar
• Keniston R, Enriquez JI Sr. Relationship between blood pressure and plasma vitamin B6 levels in healthy middle-aged adults. Ann. NY Acad. Sci.585, 499–501 (1990).
   Web of Science ®Google Scholar
• Aybak M, Sermet A, Ayyildiz MO, Karakilcik AZ. Effect of oral pyridoxine hydrochloride supplementation on arterial blood pressure in patients with essential hypertension. Arzneimittelforschung45, 1271–1273 (1995).
   PubMed Web of Science ®Google Scholar
• Moline J, Bukharovich IF, Wolff MS, Phillips R. Dietary flavonoids and hypertension: is there a link? Med. Hypotheses55, 306–309 (2000).
   PubMed Web of Science ®Google Scholar
• Knekt P, Reunanen A, Järvinen R, Seppänen R, Heliövaara M, Aromaa A. Antioxidant vitamin intake and coronary mortality in a longitudinal population study. Am. J. Epidemiol.139, 1180–1189 (1994).
   PubMed Web of Science ®Google Scholar
• Karatzi KN, Papamichael CM, Karatizis EN et al. Red wine acutely induces favorable effects on wave reflections and central pressures in coronary artery disease patients. Am. J. Hypertens.18(9), 1161–1167 (2005).
   PubMed Web of Science ®Google Scholar
• Paran E, Engelhard YN. Effect of lycopene, an oral natural antioxidant on blood pressure. J. Hypertens.19, S74 (2001) (Abstract P 1.204).
   Google Scholar
• Engelhard YN, Gazer B, Paran E. Natural antioxidants from tomato extract reduce blood pressure in patients with grade-1 hypertension: a double blind placebo controlled pilot study. Am. Heart J.151(1), 100 (2006).
   PubMed Web of Science ®Google Scholar
• Paran E, Novac C, Engelhard YN, Hazan-Halevy I. The effects of natural antioxidants form tomato extract in treated but uncontrolled hypertensive patients. Cardiovasc. Drugs Ther.23(2), 145–151 (2009).
   PubMed Web of Science ®Google Scholar
• Reid K, Frank OR, Stocks NP. Dark chocolate or tomato extract for prehypertension: a randomized controlled trial. BMC Complement. Altern Med.9, 22 (2009).
   PubMedGoogle Scholar
• Paran E, Engelhard Y. Effect of tomato’s lycopene on blood pressure, serum lipoproteins, plasma homocysteine and oxidative stress markers in grade I hypertensive patients. Am. J. Hypertens.14, 141A (2001) (Abstract P-333).
   PubMed Web of Science ®Google Scholar
• Langsjoen PH, Langsjoen AM. Overview of the use of Co Q 10 in cardiovascular disease. Biofactors9, 273–284 (1999).
   PubMed Web of Science ®Google Scholar
• Singh RB, Niaz MA, Rastogi SS, Shukla PK, Thakur AS. Effect of hydrosoluble coenzyme Q10 on blood pressure and insulin resistance in hypertensive patients with coronary heart disease. J. Hum. Hypertens.12, 203–208 (1999).
   Web of Science ®Google Scholar
• Burke BE, Neustenschwander R, Olson RD. Randomized, double-blind, placebo-controlled trial of coenzyme Q10 in isolated systolic hypertension. South. Med. J.94, 1112–1117 (2001).
   PubMed Web of Science ®Google Scholar
• Rosenfeldt FL, Haas SJ, Krum H et al. Coenzyme Q 10 in the treatment of hypertension: a meta-analysis of the clinical tials. J. Hum. Hypertens.21(4), 297–306 (2007).
   PubMed Web of Science ®Google Scholar
• Singh RB, Niaz MA, Rastogi SS, Shukia PK, Thakur AS. Effect of hydrosoluble coenzyme Q 10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. J. Hum. Hypertens.13(3), 302–308 (1999).
   Google Scholar
• Ankola DD, Viswanas B, Bhardqaj V, Ramarao P, Kumar MN. Development of potent oral nanoparticulate formulation of coenzyme Q10 for treatment of hypertension: can the simple nuttitional supplement be used as first line therapeutic agents for prophylaxis/therapy? Eur. J. Pharm. Biopharm.67(2), 361–369 (2007).
   PubMed Web of Science ®Google Scholar
• McMackin CJ, Widlansky ME, Hambury NM, Haung AL. Effect of combined treatment with α-lipoic acid and acetyl carnitine on vascular function and blood pressure in patients with coronary artery disease. J. Clin. Hypertens.9, 249–255 (2007).
   PubMedGoogle Scholar
• Siani A, Pagano E, Iacone R, Iacoviell L, Scopacasa F, Strazzullo P. Blood pressure and metabolic changes during dietary l-arginine supplementation in humans. Am. J. Hypertens.13, 547–551 (2000).
   PubMed Web of Science ®Google Scholar
• Vallance P, Leone A, Calver A, Collier J, Moncada S. Endogenous dimethyl-arginine as an inhibitor of nitric oxide synthesis. J. Cardiovasc. Pharmacol.20, S60–S62 (1992).
   PubMed Web of Science ®Google Scholar
• Digiesi V, Cantini F, Bisi G, Guarino G, Brodbeck B. l-carnitine adjuvant therapy in essential hypertension. Clin. Ter.144, 391–395 (1994).
   PubMedGoogle Scholar
• Huxtable RJ. Physiologic actions of taurine. Physiol. Rev.72, 101–163 (1992).
   PubMed Web of Science ®Google Scholar
• Fujita T, Ando K, Noda H, Ito Y, Sato Y. Effects of increased adrenomedullary activity and taurine in young patients with borderline hypertension. Circulation75, 525–532 (1987).
   PubMed Web of Science ®Google Scholar
• Huxtable RJ, Sebring LA. Cardiovascular actions of taurine. Prog. Clin. Biol. Res.125, 5–37 (1983).
   PubMedGoogle Scholar
• Tanabe Y, Urata H, Kiyonaga A et al. Changes in serum concentrations of taurine and other amino acids in clinical antihypertensive exercise therapy. Clin. Exp. Hypertens.11, 149–165 (1989).
   Web of Science ®Google Scholar
• Hosseini S, Lee J, Sepulveda RT et al. A randomized, double-blind, placebo-controlled, prospective 16 week crossover study to determine the role of pycnogenol in modifying blood pressure in mildly hypertensive patients. Nutr. Res.21, 1251–1260 (2001).
   Web of Science ®Google Scholar
• Zibadi S, Rohdewald PJ, Park D, Watson RR. Reduction of cardiovascular risk factors in subjects with Type 2 diabetes by pycnogenol supplementation. Nutr. Res.28(5), 315–320 (2008).
   PubMed Web of Science ®Google Scholar
• Liu X, Wei J, Tan F, Zhou S, Wurthwein G, Rohdewald P. Pycnogenol French maritime pine bark extract improves endothelial function of hypertensive patients. Life Sci.74(7), 855–862 (2004).
   PubMed Web of Science ®Google Scholar